Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure

Table 4 Coagulation indices in the two groups

Group	PT (s)		APTT (s)		TT (s)		INR (s)		FIB (g/L)
	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment	Pre-treatment	Post-treatment
Observation group (n = 33)	16.25 ± 0.26	12.35 ± 0.56b	40.12 ± 0.13	36.65 ± 0.23b	21.48 ± 0.89	17.56 ± 0.48b	2.31 ± 0.13	0.94 ± 0.05b	6.17 ± 0.19	5.26 ± 0.11b
Control group (n = 32)	16.29 ± 0.33	15.48 ± 0.48b	40.17 ± 0.19	39.48 ± 0.24b	21.15 ± 0.78	20.03 ± 0.26b	2.32 ± 0.19	2.01 ± 0.12b	6.13 ± 0.56	3.26 ± 0.56b
t	0.543	24.160	1.241	48.544	1.587	25.680	0.248	47.181	0.388	20.124
P value	0.588	< 0.001	0.219	< 0.001	0.117	< 0.001	0.804	< 0.001	0.699	< 0.001

^bP < 0.001 in comparison with the pre-treatment value. Data are presented as mean ± SD. PT: Prothrombin time; APTT: Activated partial thromboplastin time; TT: Thrombin time; INR: International normalized ratio; FIB: Fibrinogen.